Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,186.10 -1.60 (-0.03%) Dow
39,028.97 +144.71 (+0.37%) Nasdaq
16,299.26 -33.29 (-0.20%) Bitcoin USD
62,475.00 -637.63 (-1.01%) CMC Crypto 200
1,328.17 +33.50 (+2.59%)
BLUE May 2024 7.500 put
| Previous close | 4.6000 |
| Open | 4.6000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 7.50 |
| Expiry date | 2024-05-17 |
| Day's range | 4.6000 - 4.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business Wirebluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
SOMERVILLE, Mass., May 06, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET.
Business Wirebluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
SOMERVILLE, Mass., May 06, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive events. LYFGENIA was approved by the FDA in December 2023 and is the most deeply studied gene therapy for sickle cell disease, with the longest follow-up in the field.
Business Wirebluebird bio Announces Receipt of Expected Notice from Nasdaq
SOMERVILLE, Mass., April 26, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received a notice (the "notice") on April 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"), it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports wi
